Want to see IBIO full AI Analyst Report?
IBIO Stock Chart & Stats
$2.06
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.06
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $3.82
Previous CloseN/A
Volume55.53K
Average Volume (3M)813.89K
Market Cap
$86.94M
Enterprise Value-$20.04M
Total Cash (Recent Filing)$74.80M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Sep 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding49,678,562
10 Day Avg. Volume903,055
30 Day Avg. Volume813,893
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-66.81
Enterprise Value/Gross Profit41.76
Enterprise Value/Ebitda0.76
Forecast
1Y Price Target
$5.67Price Target Upside175.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Advancing Pipeline To Clinical StageTransitioning IBIO-600 into first-in-human trials marks a durable step from discovery to clinical development. Clinical-stage status creates definable regulatory and clinical milestones that can unlock partnerships, non-dilutive milestones, and de-risk certain preclinical uncertainties over the next 2–6 months.
Promising Preclinical IBIO-610 DataRobust NHP biomarker and mechanistic data showing near-complete pathway suppression and preservation of lean mass support a differentiated, durable therapeutic profile. Mechanism-based differentiation and compatibility with GLP-1s create a sustainable strategic position in obesity therapeutics.
Low Leverage And Meaningful Equity BaseMinimal financial leverage reduces fixed interest burden and bankruptcy risk, providing strategic flexibility to prioritize R&D and partnerships. A meaningful equity base supports funding options and negotiation leverage for collaborations over the medium term.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow indicate the business cannot self-fund development. Ongoing cash burn constrains runway, forces recurring capital raises, and limits the company's ability to scale internal programs or withstand trial setbacks without dilutive financing.
Minimal Revenue, Large Operating LossesVery low revenue and substantial operating losses reflect lack of commercialized products and scale. This structural lack of operating profitability undermines margin sustainability and means strategic progress hinges on clinical success and external funding rather than internal cash generation.
Dependence On External FinancingA business model reliant on equity raises, licensing, or milestone payments creates persistent dilution risk and strategic uncertainty. Dependence on capital markets and partners can delay programs, alter timelines, and impair long-term planning if market access tightens or milestones slip.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $3.82 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $86.94M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Sep 29, 2026 which is in 88 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on May 12, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 49,678,562 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went down -3.727%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (175.08% Upside)
$5.67 (175.08% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
129.35%
12-Months-Change
Fundamentals
Return on Equity
-53.86%
Trailing 12-Months
Asset Growth
349.32%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.67
▲(175.08% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.61% Insiders
2.62% Mutual Funds
22.49% Other Institutional Investors
71.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---